Endometrial carcinoma (EC) ranks as one of the most frequent gynecological malignancies, and the incidence continues to rise.1 EC is broadly categorized into two subtypes, type I endometrioid adenocarcinoma (EEC) and type II non-EEC (NEEC), based on histological features, hormone receptor status and grade.2 EEC, the most common subtype, is a low-grade, hormone receptor-positive tumor that typically coexists with or is preceded by endometrial hyperplasia. This evidence concerns the gene NR4A1 and endometrioid adenocarcinoma.